Hormone Therapy Restores Bone in Diabetic Mice

A mouse study found parathyroid hormone and abaloparatide rebuilt jawbone lost to type 2 diabetes.

Updated on Nov. 12, 2026 in Diabetes

Bold flat-color editorial illustration of a jawbone cross-section with its porous inner structure being rebuilt, set against a plain teal field.
Researchers found parathyroid hormone and abaloparatide restored jawbone lost to type 2 diabetes in mice, a possible route to preserving teeth. AI Illustration. Upload story photo >

Researchers reported in the International Journal of Oral Science that parathyroid hormone and abaloparatide restored alveolar bone in mice with established type 2 diabetes. Alveolar bone supports the teeth, and its loss in diabetes can lead to tooth loosening and loss.

Why it matters

Diabetic patients face a substantially higher risk of periodontitis, and the study suggests a possible route to preserving tooth retention and supporting dental implants. The findings remain preclinical and come from mouse models.

The study used a mouse model of type 2 diabetes induced by high-fat diet and streptozotocin, with bone measured by micro-computed tomography and histology. Whether these results carry over to human patients has not been tested, and the researchers call for further work on the pathways involved.

The players

Indiana University School of Medicine

A medical school in Indianapolis, Indiana, affiliated with Indiana University, that conducted the research.

University of Arkansas for Medical Sciences

A public academic medical center in Little Rock, Arkansas, that co-led the research.

The details

The researchers, from Indiana University School of Medicine and the University of Arkansas for Medical Sciences, found that PTH and abaloparatide suppressed sclerostin and Dickkopf-1 in osteocytes, activating Wnt signaling. The anabolic effect depended on PTH1R signaling in osteocytes, while bone resorption was driven by PTH1R in marrow cells through RANKL upregulation.

Timeline

  1. 29 October 2026: Study published in the International Journal of Oral Science.

Health Landscape

The study extends the established use of PTH-family drugs such as abaloparatide, approved for osteoporosis, into the treatment of diabetes-related jawbone loss. It points toward repurposing existing bone-anabolic therapies for oral health complications that affect people with type 2 diabetes.

Any future use would likely depend on clinical trials in people, which have not yet been conducted. For now, the findings do not change how people with diabetes should manage their dental care.

The takeaway

Dental health is part of diabetes care, and bone loss in the jaw is a real complication. Patients with diabetes should keep up regular dental checkups and discuss gum or tooth concerns with their dentist.

Further reading

Explore more on Diabetes to see how the disease affects bones, teeth, and other parts of the body.

More information

Read the full published study in International Journal of Oral Science.